ThermoGenesis (THMO) 10-Q 13 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 11, 2021
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		11,911,784
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 10,014,000	$ 7,161,000
Accounts receivable, net of allowance for doubtful accounts of $214,000 and at December 31, 2020	826,000	1,382,000
Inventories	5,334,000	5,877,000
Prepaid expenses and other current assets	730,000	878,000
Total current assets	16,904,000	15,298,000
Inventories, non-current	2,486,000	1,221,000
Equipment and leasehold improvements, net	1,337,000	1,424,000
Right-of-use operating lease assets, net	693,000	730,000
Goodwill	781,000	781,000
Other intangible assets, net	1,342,000	1,358,000
Other assets	48,000	48,000
Total assets	23,591,000	20,860,000
Current liabilities:
Accounts payable	1,328,000	1,366,000
Accrued payroll and related expenses	473,000	349,000
Deferred revenue – short-term	696,000	608,000
Convertible promissory note – related party, net	6,762,000
Interest payable – related party	550,000	2,082,000
Note payable – short-term		447,000
Other current liabilities	682,000	1,291,000
Total current liabilities	10,491,000	6,143,000
Convertible promissory note – related party, net		5,935,000
Convertible promissory note, net	572,000	493,000
Note payable		199,000
Operating lease obligations – long-term	558,000	604,000
Deferred revenue – long-term	1,520,000	1,596,000
Other noncurrent liabilities	20,000	20,000
Total liabilities	13,161,000	14,990,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 11,911,784 issued and outstanding (8,934,952 at December 31, 2020)	12,000	9,000
Additional paid in capital	266,145,000	259,058,000
Accumulated deficit	(255,696,000)	(253,283,000)
Accumulated other comprehensive loss	17,000	16,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	10,478,000	5,800,000
Noncontrolling interests	(48,000)	70,000
Total equity	10,430,000	5,870,000
Total liabilities and equity	$ 23,591,000	$ 20,860,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 214,000	$ 214,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	11,911,784	8,934,952
Common stock, shares outstanding (in shares)	11,911,784	8,934,952

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenues	$ 1,517,000	$ 3,200,000
Cost of revenues	809,000	1,708,000
Gross profit	708,000	1,492,000
Expenses:
Selling, general and administrative	1,992,000	2,092,000
Research and development	379,000	609,000
Total operating expenses	2,371,000	2,701,000
Loss from operations	(1,663,000)	(1,209,000)
Other income (expenses):
Interest expense	(1,519,000)	(3,531,000)
Other income (expenses)	(1,000)	(3,000)
Gain on extinguishment of debt	652,000
Total other expenses	(868,000)	(3,534,000)
Net loss	(2,531,000)	(4,743,000)
Loss attributable to noncontrolling interests	(118,000)	(141,000)
Net loss attributable to common stockholders	(2,413,000)	(4,602,000)
Net loss	(2,531,000)	(4,743,000)
Other comprehensive loss:
Foreign currency translation gain	1,000	38,000
Comprehensive loss	(2,530,000)	(4,705,000)
Comprehensive loss attributable to noncontrolling interests	(118,000)	(141,000)
Comprehensive loss attributable to common stockholders	$ (2,412,000)	$ (4,564,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.21)	$ (1.11)
Weighted average common shares outstanding basic and diluted (in shares)	11,446,366	4,135,644

Condensed Consolidated Statemen

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	At The Market Offering Agreement [Member]Common Stock [Member]	At The Market Offering Agreement [Member]Additional Paid-in Capital [Member]	At The Market Offering Agreement [Member]Retained Earnings [Member]	At The Market Offering Agreement [Member]AOCI Attributable to Parent [Member]	At The Market Offering Agreement [Member]Noncontrolling Interest [Member]	At The Market Offering Agreement [Member]	Registered Direct Offering [Member]Common Stock [Member]	Registered Direct Offering [Member]Additional Paid-in Capital [Member]	Registered Direct Offering [Member]Retained Earnings [Member]	Registered Direct Offering [Member]AOCI Attributable to Parent [Member]	Registered Direct Offering [Member]Noncontrolling Interest [Member]	Registered Direct Offering [Member]	Boyalife Asset Holding II [Member]Common Stock [Member]	Boyalife Asset Holding II [Member]Additional Paid-in Capital [Member]	Boyalife Asset Holding II [Member]Retained Earnings [Member]	Boyalife Asset Holding II [Member]AOCI Attributable to Parent [Member]	[1]	Boyalife Asset Holding II [Member]Noncontrolling Interest [Member]	Boyalife Asset Holding II [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2019																				2,843,601
Balance at Dec. 31, 2019																				$ 3,000	$ 237,313,000	$ (236,932,000)	$ 2,000	[1]	$ 530,000	$ 916,000
Stock-based compensation expense																					67,000					67,000
Issuance of common stock (in shares)	50,746						1,000,002
Issuance of common stock		$ 114,000				$ 114,000	$ 1,000	$ 3,106,000				$ 3,107,000
Foreign currency translation gain (loss)																							38,000			38,000
Net loss																						(4,602,000)		[1]	(141,000)	(4,743,000)
Exercise of pre-funded warrants (in shares)																				100,000
Exercise of pre-funded warrants																					10,000			[1]		10,000
Exercise of warrants (in shares)																				7,866
Exercise of warrants																					47,000			[1]		47,000
Discount due to beneficial conversion features																					1,869,000			[1]		1,869,000
Conversion of note payable to common stock (in shares)													1,666,670							100,000
Conversion of note payable to common stock													$ 2,000	$ 2,998,000					$ 3,000,000		180,000			[1]		180,000
Foreign currency translation gain																							38,000			38,000
Balance (in shares) at Mar. 31, 2020																				5,768,885
Balance at Mar. 31, 2020																				$ 6,000	245,704,000	(241,534,000)	40,000		389,000	4,605,000
Balance (in shares) at Dec. 31, 2020																				8,934,952
Balance at Dec. 31, 2020																				$ 9,000	259,058,000	(253,283,000)	16,000	[1]	70,000	5,870,000
Stock-based compensation expense																					258,000			[1]		258,000
Issuance of common stock (in shares)	2,976,832					2,976,832
Issuance of common stock	$ 3,000	$ 6,829,000				$ 6,832,000
Foreign currency translation gain (loss)																							1,000	[1]		1,000
Net loss																						(2,413,000)		[1]	(118,000)	(2,531,000)
Foreign currency translation gain																							1,000	[1]		1,000
Balance (in shares) at Mar. 31, 2021																				11,911,784
Balance at Mar. 31, 2021																				$ 12,000	$ 266,145,000	$ (255,696,000)	$ 17,000	[1]	$ (48,000)	$ 10,430,000
[1]	Accumulated other comprehensive loss.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (2,531,000)	$ (4,743,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	166,000	199,000
Stock-based compensation expense	258,000	67,000
Amortization of debt discount/premium	908,000	522,000
Amortization of accelerated debt discount due to conversion		2,486,000
Reserve for excess and slow-moving inventories	(4,000)	6,000
Reserve for bad debt expense		1,000
Gain on extinguishment of debt	(652,000)
Net change in operating assets and liabilities:
Accounts receivable	556,000	(752,000)
Inventories	(718,000)	(400,000)
Prepaid expenses and other assets	148,000	330,000
Accounts payable	(38,000)	1,035,000
Interest payable – related party	(1,532,000)	(1,426,000)
Accrued payroll and related expenses	124,000	118,000
Deferred revenue – short term	88,000	(3,000)
Other current liabilities	(603,000)	129,000
Long-term deferred revenue and other noncurrent liabilities	(122,000)	(110,000)
Net cash used in operating activities	(3,952,000)	(2,541,000)
Cash flows from investing activities:
Capital expenditures	(27,000)	(23,000)
Net cash used in investing activities	(27,000)	(23,000)
Cash flows from financing activities:
Proceeds from convertible promissory note-related party		1,869,000
Payment on finance lease obligations		(13,000)
Proceeds from issuance of common stock, net of expenses	6,832,000	3,220,000
Proceeds from the exercise of options, warrants and pre-funded warrants		57,000
Net cash provided by financing activities	6,832,000	5,133,000
Effects of foreign currency rate changes on cash and cash equivalents		(5,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	2,853,000	2,562,000
Cash, cash equivalents and restricted cash at beginning of period	7,161,000	4,157,000
Cash, cash equivalents and restricted cash at end of period	10,014,000	6,719,000
Supplemental disclosures of cash flow information:
Cash paid for interest	2,142,000	1,950,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt		1,869,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Supplemental non-cash financing and investing information:
Related party promissory note converted to common stock		3,000,000
Conversion of January 2019 Amended Notes to Common Stock [Member]
Supplemental non-cash financing and investing information:
Related party promissory note converted to common stock		$ 180,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products: Clinical Bio-Banking Applications: ● AXP® 510 ● BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510 Point-of-Care Applications: ● PXP® 510 ● PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510 ● PXP- 1000 510 Large Scale Cell Processing and Biomanufacturing: ● X X X X X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three March 31, 2021 not may December 31, 2021. 10 December 31, 2020. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp's majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% not 80%

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. GOING CONCERN At March 31, 2021, $10,014,000 $6,413,000. March 31, 2021 $255,696,000. one may may The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company's ability to do so. The condensed consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES There have been no 2020 Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020. not three March 31, 2021 not In January 2020, 2020 01, Investments Equity Securities (Topic 321 Equity Method and Joint Ventures (Topic 323 815 321, 323, 815 December 15, 2020, not Revenue Recognition Revenue is recognized based on the five 606: Disaggregation of Revenue The Company's primary revenue streams include device sales and service revenue from device maintenance contracts, as summarized in the following table: Three Months Ended March 31, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 225,000 $ 39,000 $ -- $ 264,000 BioArchive 208,000 542,000 -- 750,000 CAR-TXpress 255,000 28,000 71,000 354,000 Manual Disposables 129,000 -- -- 129,000 Other 7,000 -- 13,000 20,000 Total $ 824,000 $ 609,000 $ 84,000 $ 1,517,000 Three Months Ended March 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,208,000 $ 24,000 $ -- $ 2,232,000 BioArchive 164,000 332,000 -- 496,000 CAR-TXpress 152,000 12,000 71,000 235,000 Manual Disposables 203,000 -- -- 203,000 Other 14,000 -- 20,000 34,000 Total $ 2,741,000 $ 368,000 $ 91,000 $ 3,200,000 Performance Obligations In most cases, there is no no Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2021 $273,000. $696,000 $608,000 March 31, 2021 December 31, 2020, $1,520,000 $1,596,000 March 31, 2021 December 31, 2020, Exclusivity Fee On August 30, 2019, five two X $2,000,000 three March 31, 2021 2020, $71,000 $2,000,000 $1,548,000 $286,000 $1,262,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 1,013,000 $ 804,000 $ 412,000 $ 152,000 $ 85,000 $ 2,466,000 Clinical revenue 10,000 13,000 13,000 13,000 162,000 211,000 Exclusivity fee 214,000 286,000 286,000 286,000 476,000 1,548,000 Total $ 1,237,000 $ 1,103,000 $ 711,000 $ 451,000 $ 723,000 $ 4,225,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3 Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not three March 31, 2021, one

Note 4 - Net Loss Per Share

Note 4 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	4. NET LOSS PER SHARE Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 224,445 March 31, 2020 The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company's net loss position for all periods presented. Anti-dilutive securities consisted of the following at March 31: 2021 2020 Common stock equivalents of convertible promissory note and accrued interest 6,449,950 5,159,496 Vested Series A warrants -- 40,441 Unvested Series A warrants (1) -- 69,853 Warrants – other 653,248 1,273,461 Stock options 889,636 287,849 Total 7,992,834 6,831,100 ___________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	5. RELATED PARTY TRANSACTIONS HealthBanks Biotech (USA) Inc. On November 26, 2019 80% 20% Between November 26, 2019 September 30, 2020, 75.16% 18.79% 6.05% In March 2021, 12,000,000 500,000 18.79% 8.64%. none $262,000 March 31, 2021, $428,000 no March 31, 2021. For the quarter ended March 31, 2021 2020, $0 $13,000, March 31, 2021, $0. March 31, 2021, $253,000, $3,514,000 $2,375,000. Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( March 31, 2021 December 31, 2020, $10,000,000. The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five January 2021, December 31, 2020 $2,082,000. The Credit Agreement and Note were amended in April 2018, $16.10 2018, $1.80. The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At March 31, 2021 3/6/2022 22% $ 1.80 $ 10,000,000 $ (3,238,000 ) $ 6,762,000 At December 31, 2020 3/6/2022 22% $ 1.80 $ 10,000,000 $ (4,065,000 ) $ 5,935,000 The Company amortized $827,000 $546,000 three March 31, 2021 2020, $550,000 $443,000 three March 31, 2021 2020, March 31, 2021 December 31, 2020 $550,000 $2,082,000,

Note 6 - Convertible Promissory

Note 6 - Convertible Promissory Notes	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	6. CONVERTIBLE PROMISSORY NOTE July 2019 On July 23, 2019, $1,000,000 “July 2019 July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. The following summarizes the July 2019 Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At March 31, 2021 7/31/2022 24% $ 1.80 $ 1,000,000 $ (428,000 ) $ 572,000 At December 31, 2020 7/31/2022 24% $ 1.80 $ 1,000,000 $ (507,000 ) $ 493,000 The Company recorded amortization expense of $80,000 July 2019 three March 31, 2021 $60,000 three March 31, 2021 2020.

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. LEASES The Company leases an approximately 28,000 first 2019 May 2024. Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company's operating leases: March 31, 2021 December 31, 2020 Right-of-use operating lease assets, net $ 693,000 $ 730,000 Current lease liability (included in other current liabilities) 168,000 157,000 Non-current lease liability 558,000 604,000 Weighted average remaining lease term 3.2 3.4 Discount rate 22 % 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2021 (Remaining) $ 234,000 2022 319,000 2023 328,000 2024 139,000 Total lease payments $ 1,020,000 Less: imputed interest (294,000 ) Present value of operating lease liabilities $ 726,000 Statement of Cash Flows In January 2019, $966,000 $76,000 $74,000 March 31, 2021 2020, Operating Lease Costs Operating lease costs were $109,000 $103,000 March 31, 2021 2020, Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases were not March 31, 2021 March 31, 2020.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES Contingencies In the normal course of operations, the Company may March 31, 2021, may not Financial Covenants On July 13, 2020, #2 July 13, 2020 ( May 15, 2017 #1 March 16, 2020 one $1,000,000 March 31, 2021. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the three March 31, 2021 Balance at December 31, 2020 $ 154,000 Warranties issued during the period 6,000 Settlements made during the period (66,000 ) Changes in liability for pre-existing warranties during the period 12,000 Balance at March 31, 2021 $ 106,000

Note 9 - Payment Protection Pro

Note 9 - Payment Protection Program	3 Months Ended
	Mar. 31, 2021
Paycheck Protection Program CARES Act [Member]
Notes to Financial Statements
Long-term Debt [Text Block]	9. PAYMENT PROTECTION PROGRAM On April 21, 2020, $646,000 two 1.00% first six may may December 2020, March 30, 2021 three March 31, 2021, $652,000

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. STOCKHOLDERS EQUITY Common Stock On December 13, 2019, may $4,400,000 May 19, 2020 $15,280,313 March 31, 2021, 5,597,484 $15,280,000 $2.73 $14,568,000 $712,000. three March 31, 2021, 2,976,832 $6,832,000 $224,000 Stock Based Compensation The Company recorded stock-based compensation of $258,000 $67,000 three March 31, 2021 2020, Three Months Ended March 31, 2021 2020 Cost of goods sold $ 5,000 $ -- Sales, general and administrative 216,000 52,000 Research and development 37,000 15,000 $ 258,000 $ 67,000 The following is a summary of option activity for the Company's stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 889,636 $ 8.57 Forfeited -- Outstanding at March 31, 2021 889,636 8.57 8.5 $ -- Vested and expected to vest at March 31, 2021 631,053 $ 9.54 8.3 $ -- Exercisable at March 31, 2021 230,836 $ 15.21 7.2 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock. There were no three March 31, 2021. Warrants A summary of warrant activity for the three March 31, 2021 Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2020 1,116,484 $ 37.27 0.49 Warrants expired 463,236 Warrants exercised -- $ -- Outstanding at March 31, 2021 653,248 $ 6.97 2.20 Exercisable at March 31, 2021 653,248 $ 6.97 2.20

Note 11 - Major Customers and A

Note 11 - Major Customers and Accounts Receivable	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	11. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE The Company had certain customers whose revenue individually represented 10% 10% For the three March 31, 2021 2020, one 21% 2% second 15% 6% third 3% 50%, At March 31, 2021, three 67% December 31, 2020, three 72%

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	12. SUBSEQUENT EVENTS The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020. not three March 31, 2021 not In January 2020, 2020 01, Investments Equity Securities (Topic 321 Equity Method and Joint Ventures (Topic 323 815 321, 323, 815 December 15, 2020, not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Disaggregation of Revenue The Company's primary revenue streams include device sales and service revenue from device maintenance contracts, as summarized in the following table: Three Months Ended March 31, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 225,000 $ 39,000 $ -- $ 264,000 BioArchive 208,000 542,000 -- 750,000 CAR-TXpress 255,000 28,000 71,000 354,000 Manual Disposables 129,000 -- -- 129,000 Other 7,000 -- 13,000 20,000 Total $ 824,000 $ 609,000 $ 84,000 $ 1,517,000 Three Months Ended March 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,208,000 $ 24,000 $ -- $ 2,232,000 BioArchive 164,000 332,000 -- 496,000 CAR-TXpress 152,000 12,000 71,000 235,000 Manual Disposables 203,000 -- -- 203,000 Other 14,000 -- 20,000 34,000 Total $ 2,741,000 $ 368,000 $ 91,000 $ 3,200,000 Performance Obligations In most cases, there is no no Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2021 $273,000. $696,000 $608,000 March 31, 2021 December 31, 2020, $1,520,000 $1,596,000 March 31, 2021 December 31, 2020, Exclusivity Fee On August 30, 2019, five two X $2,000,000 three March 31, 2021 2020, $71,000 $2,000,000 $1,548,000 $286,000 $1,262,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 1,013,000 $ 804,000 $ 412,000 $ 152,000 $ 85,000 $ 2,466,000 Clinical revenue 10,000 13,000 13,000 13,000 162,000 211,000 Exclusivity fee 214,000 286,000 286,000 286,000 476,000 1,548,000 Total $ 1,237,000 $ 1,103,000 $ 711,000 $ 451,000 $ 723,000 $ 4,225,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not three March 31, 2021, one

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 225,000 $ 39,000 $ -- $ 264,000 BioArchive 208,000 542,000 -- 750,000 CAR-TXpress 255,000 28,000 71,000 354,000 Manual Disposables 129,000 -- -- 129,000 Other 7,000 -- 13,000 20,000 Total $ 824,000 $ 609,000 $ 84,000 $ 1,517,000 Three Months Ended March 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,208,000 $ 24,000 $ -- $ 2,232,000 BioArchive 164,000 332,000 -- 496,000 CAR-TXpress 152,000 12,000 71,000 235,000 Manual Disposables 203,000 -- -- 203,000 Other 14,000 -- 20,000 34,000 Total $ 2,741,000 $ 368,000 $ 91,000 $ 3,200,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 1,013,000 $ 804,000 $ 412,000 $ 152,000 $ 85,000 $ 2,466,000 Clinical revenue 10,000 13,000 13,000 13,000 162,000 211,000 Exclusivity fee 214,000 286,000 286,000 286,000 476,000 1,548,000 Total $ 1,237,000 $ 1,103,000 $ 711,000 $ 451,000 $ 723,000 $ 4,225,000

Note 4 - Net Loss Per Share (Ta

Note 4 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2021 2020 Common stock equivalents of convertible promissory note and accrued interest 6,449,950 5,159,496 Vested Series A warrants -- 40,441 Unvested Series A warrants (1) -- 69,853 Warrants – other 653,248 1,273,461 Stock options 889,636 287,849 Total 7,992,834 6,831,100

Note 5 - Related Party Transa_2

Note 5 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At March 31, 2021 3/6/2022 22% $ 1.80 $ 10,000,000 $ (3,238,000 ) $ 6,762,000 At December 31, 2020 3/6/2022 22% $ 1.80 $ 10,000,000 $ (4,065,000 ) $ 5,935,000

Note 6 - Convertible Promisso_2

Note 6 - Convertible Promissory Notes (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Convertible Debt [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At March 31, 2021 7/31/2022 24% $ 1.80 $ 1,000,000 $ (428,000 ) $ 572,000 At December 31, 2020 7/31/2022 24% $ 1.80 $ 1,000,000 $ (507,000 ) $ 493,000

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	March 31, 2021 December 31, 2020 Right-of-use operating lease assets, net $ 693,000 $ 730,000 Current lease liability (included in other current liabilities) 168,000 157,000 Non-current lease liability 558,000 604,000 Weighted average remaining lease term 3.2 3.4 Discount rate 22 % 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 (Remaining) $ 234,000 2022 319,000 2023 328,000 2024 139,000 Total lease payments $ 1,020,000 Less: imputed interest (294,000 ) Present value of operating lease liabilities $ 726,000

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2020 $ 154,000 Warranties issued during the period 6,000 Settlements made during the period (66,000 ) Changes in liability for pre-existing warranties during the period 12,000 Balance at March 31, 2021 $ 106,000

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2021 2020 Cost of goods sold $ 5,000 $ -- Sales, general and administrative 216,000 52,000 Research and development 37,000 15,000 $ 258,000 $ 67,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 889,636 $ 8.57 Forfeited -- Outstanding at March 31, 2021 889,636 8.57 8.5 $ -- Vested and expected to vest at March 31, 2021 631,053 $ 9.54 8.3 $ -- Exercisable at March 31, 2021 230,836 $ 15.21 7.2 $ --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2020 1,116,484 $ 37.27 0.49 Warrants expired 463,236 Warrants exercised -- $ -- Outstanding at March 31, 2021 653,248 $ 6.97 2.20 Exercisable at March 31, 2021 653,248 $ 6.97 2.20

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual) - CAR-TXpress [Member]	Mar. 31, 2021
Noncontrolling Interest, Ownership Percentage by Parent	80.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 10,014,000	$ 7,161,000
Working Capital	6,413,000
Retained Earnings (Accumulated Deficit), Ending Balance	$ (255,696,000)	$ (253,283,000)

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Aug. 30, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Contract with Customer, Liability, Revenue Recognized		$ 273,000
Contract with Customer, Liability, Current		696,000		$ 608,000
Contract with Customer, Liability, Noncurrent		1,520,000		$ 1,596,000
Exclusivity Fee [Member]
Contract with Customer, Liability, Revenue Recognized		71,000	$ 71,000
Contract with Customer, Liability, Current		286,000
Contract with Customer, Liability, Noncurrent		1,262,000
Contract with Customer, Liability, Total		1,548,000
Supply Agreement [Member]
Supply Agreement, Term (Year)	5 years
Supply Agreement, Renewal Term (Year)	2 years
Contract with Customer, Liability, Total	$ 2,000,000
Proceeds from Customers		$ 2,000,000

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenues	$ 1,517,000	$ 3,200,000
Device [Member] | AXP [Member]
Net revenues	264,000	2,232,000
Device [Member] | BioArchive [Member]
Net revenues	750,000	496,000
Device [Member] | CAR-TXpress [Member]
Net revenues	354,000	235,000
Device [Member] | Manual Disposables [Member]
Net revenues	129,000	203,000
Device [Member] | Other Subsegments [Member]
Net revenues	20,000	34,000
Device Revenue [Member]
Net revenues	824,000	2,741,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	225,000	2,208,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	208,000	164,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	255,000	152,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	129,000	203,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	7,000	14,000
Service [Member]
Net revenues	609,000	368,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	39,000	24,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	542,000	332,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	28,000	12,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Other [Member]
Net revenues	84,000	91,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000	71,000
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	$ 13,000	$ 20,000

Note 3 - Summary of Significa_5

Note 3 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Mar. 31, 2021USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,225,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,466,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	211,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,548,000

Note 3 - Summary of Significa_6

Note 3 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Mar. 31, 2021USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,225,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	273 days
Revenue, Remaining Performance Obligation, Amount	$ 1,237,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,103,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 711,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 451,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 723,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,466,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	273 days
Revenue, Remaining Performance Obligation, Amount	$ 1,013,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 804,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 412,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 152,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 85,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 211,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	273 days
Revenue, Remaining Performance Obligation, Amount	$ 10,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 162,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,548,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	273 days
Revenue, Remaining Performance Obligation, Amount	$ 214,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 476,000

Note 4 - Net Loss Per Share (De

Note 4 - Net Loss Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	7,992,834	6,831,100
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	224,445

Note 4 - Net Loss Per Share - A

Note 4 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Anti-dilutive securities (in shares)		7,992,834	6,831,100
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		6,449,950	5,159,496
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)			40,441
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]		69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		653,248	1,273,461
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		889,636	287,849
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants remained outstanding but unvested until they expired in February 2021.

Note 5 - Related Party Transa_3

Note 5 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			12 Months Ended
	Mar. 31, 2021	Mar. 31, 2021	Mar. 17, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Apr. 28, 2020	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		$ (2,531,000)		$ (4,743,000)
Assets, Current, Total	$ 16,904,000	16,904,000			$ 15,298,000
Liabilities, Current, Total	$ 10,491,000	10,491,000			$ 6,143,000
Interest Paid, Excluding Capitalized Interest, Operating Activities		2,142,000		1,950,000
Amortization of Debt Discount (Premium)		$ 908,000		522,000
Boyalife Asset Holding II [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	22.00%	22.00%			22.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80	$ 1.80			$ 1.80				$ 1.80	$ 16.10
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity											$ 10,000,000
Long-term Line of Credit, Total							$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage					22.00%
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 2,082,000
Amortization of Debt Discount (Premium)		$ 827,000		546,000
Interest Payable	$ 550,000	550,000		$ 443,000
Interest Expense, Debt, Excluding Amortization		$ 550,000			$ 2,082,000
ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	12,000,000
ImmuneCyte [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	500,000
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage	8.64%	8.64%				18.79%		20.00%
Dilution Gain from Equity Method Investments		$ 262,000
Equity Method Investment Accumulated Gain Loss		(428,000)
Income (Loss) from Equity Method Investments, Total		0			$ 13,000
Equity Method Investment, Aggregate Cost	$ 0	0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		(253,000)
Assets, Current, Total	3,514,000	3,514,000
Liabilities, Current, Total	$ 2,375,000	$ 2,375,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage						75.16%		80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage						6.05%

Note 5 - Related Party Transa_4

Note 5 - Related Party Transactions - Summarizes the Note (Details) - Boyalife Asset Holding II [Member] - Convertible Debt [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Apr. 16, 2018
Debt Instrument, Maturity Date	Mar. 6, 2022	Mar. 6, 2022
State interest rate	22.00%	22.00%
Conversion price (in dollars per share)	$ 1.80	$ 1.80	$ 1.80	$ 16.10
Face value	$ 10,000,000	$ 10,000,000
Remaining debt discount	(3,238,000)	(4,065,000)
Carrying Value	$ 6,762,000	$ 5,935,000

Note 6 - Convertible Promisso_3

Note 6 - Convertible Promissory Notes (Details Textual) - USD ($)	Jul. 23, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Amortization of Debt Discount (Premium)		$ 908,000	$ 522,000
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000	$ 1,000,000		$ 1,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80		$ 1.80
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%	24.00%		24.00%
Amortization of Debt Discount (Premium)		$ 80,000
Interest Expense, Debt, Total		$ 60,000	$ 60,000
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.50

Note 6 - Convertible Promisso_4

Note 6 - Convertible Promissory Notes - Convertible Promissory Notes (Details) - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Jul. 23, 2019
Maturity Date	Jul. 31, 2022	Jul. 31, 2022
Stated Interest Rate	24.00%	24.00%	24.00%
Conversion Price (in dollars per share)	$ 1.80	$ 1.80
Face Value	$ 1,000,000	$ 1,000,000	$ 1,000,000
Remaining debt discount	(428,000)	(507,000)
Carrying Value	$ 572,000	$ 493,000

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 693,000		$ 730,000
Operating Lease, Payments	76,000	$ 74,000
Operating Lease, Cost	$ 109,000	$ 103,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 966,000

Note 7 - Leases - Lease Informa

Note 7 - Leases - Lease Information (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Right-of-use operating lease assets, net	$ 693,000	$ 730,000
Non-current lease liability	$ 558,000	$ 604,000
Weighted average remaining lease term (Year)	3 years 73 days	3 years 146 days
Discount rate	22.00%	22.00%
Current Liabilities [Member]
Current lease liability (included in other current liabilities)	$ 168,000	$ 157,000

Note 7 - Leases - Maturities of

Note 7 - Leases - Maturities of Lease Liabilities (Details)	Mar. 31, 2021USD ($)
2021 (Remaining)	$ 234,000
2022	319,000
2023	328,000
2024	139,000
Total lease payments	1,020,000
Less: imputed interest	(294,000)
Present value of operating lease liabilities	$ 726,000

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Jul. 13, 2020
Short Term Investment Minimum		$ 1,000,000
Minimum [Member]
Period Of Warranty On Products (Year)	1 year
Maximum [Member]
Period Of Warranty On Products (Year)	2 years

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	3 Months Ended
	Mar. 31, 2021USD ($)
Balance	$ 154,000
Warranties issued during the period	6,000
Settlements made during the period	(66,000)
Changes in liability for pre-existing warranties during the period	12,000
Balance	$ 106,000

Note 9 - Payment Protection P_2

Note 9 - Payment Protection Program (Details Textual) - USD ($)	Apr. 21, 2020	Mar. 31, 2021	Mar. 31, 2020
Gain (Loss) on Extinguishment of Debt, Total		$ 652,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 646,000
Gain (Loss) on Extinguishment of Debt, Total		$ 652,000

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($)	3 Months Ended		16 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	May 19, 2020	Dec. 13, 2019
Proceeds from Issuance of Common Stock, Net	$ 6,832,000	$ 3,220,000
Share-based Payment Arrangement, Expense	$ 258,000	$ 67,000
At The Market Offering Agreement [Member]
Maximum Offering Price for Issuance of Common Stock				$ 15,280,313	$ 4,400,000
Stock Issued During Period, Shares, New Issues (in shares)	2,976,832		5,597,484
Proceeds from Issuance of Common Stock			$ 15,280,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.73		$ 2.73
Proceeds from Issuance of Common Stock, Net	$ 6,832,000		$ 14,568,000
Payments of Stock Issuance Costs	$ 224,000		$ 712,000

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based compensation	$ 258,000	$ 67,000
Cost of Sales [Member]
Stock-based compensation	5,000
Selling, General and Administrative Expenses [Member]
Stock-based compensation	216,000	52,000
Research and Development Expense [Member]
Stock-based compensation	$ 37,000	$ 15,000

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	889,636
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 8.57
Forfeited, options (in shares) | shares
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares
Outstanding, options (in shares) | shares	889,636
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 8.57
Outstanding, weighted average remaining contractual life, options (Year)	8 years 182 days
Outstanding, aggregate intrinsic value, options | $
Vested and expected to vest, options (in shares) | shares	631,053
Vested and expected to vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 9.54
Vested and expected to vest, weighted average remaining contractual life, options (Year)	8 years 109 days
Vested and expected to vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	230,836
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 15.21
Exercisable, weighted average remaining contractual life, options (Year)	7 years 73 days
Exercisable, aggregate intrinsic value, options | $

Note 10 - Stockholders' Equit_5

Note 10 - Stockholders' Equity - Warrant Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Outstanding (in shares)	1,116,484
Outstanding, weighted average exercise price (in dollars per share)	$ 37.27
Outstanding, Weighted Average Remaining Contract Term (Year)	2 years 73 days	178 days
Warrants expired (in shares)	463,236
Warrants expired, weighted average exercise price (in dollars per share)
Warrants exercised (in shares)
Warrants exercised, weighted average exercise price (in dollars per share)
Outstanding (in shares)	653,248	1,116,484
Outstanding, weighted average exercise price (in dollars per share)	$ 6.97	$ 37.27
Exercisable (in shares)	653,248
Exercisable, weighted average exercise price (in dollars per share)	$ 6.97
Exercisable, Weighted Average Remaining Contract Term (Year)	2 years 73 days

Note 11 - Major Customers and_2

Note 11 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue Benchmark [Member] | Customer 1 [Member]
Concentration Risk, Percentage	21.00%	2.00%
Revenue Benchmark [Member] | Customer 2 [Member]
Concentration Risk, Percentage	15.00%	6.00%
Revenue Benchmark [Member] | Customer 3 [Member]
Concentration Risk, Percentage	3.00%	50.00%
Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage	67.00%		72.00%